Get the latest tech news

McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI


Atropos Health raises $33 million in Series B funding to revolutionize healthcare with AI-powered clinical evidence generation, aiming to personalize medical decision-making and accelerate drug development.

Join us in returning to NYC on June 5th to collaborate with executive leaders in exploring comprehensive methods for auditing AI models regarding bias, performance, and ethical compliance across diverse organizations. The round included strategic investments from healthcare giants McKesson, Merck, and Cencora Ventures, signaling strong industry interest in Atropos’ mission to bring automated, high-quality evidence to patient care decisions. Join us as we return to NYC on June 5th to engage with top executive leaders, delving into strategies for auditing AI models to ensure fairness, optimal performance, and ethical compliance across diverse organizations.

Get the Android app

Or read this on Venture Beat

Read more on:

Photo of M round

M round

Photo of drug development

drug development

Photo of McKesson

McKesson

Related news:

News photo

McKesson, Merck back Atropos Health’s $30M round to accelerate drug development with AI

News photo

Quintar gains new investor for $8.2M round for spatial XR

News photo

Geothermal startup Fervo Energy is tapping fresh $221M round, filing reveals